Welcome to Revvity
Welcome to Revvity, where we are expanding the boundaries of human potential through science. Together with our customers and partners, we embrace the impossible to bring this purpose to life.
Articles and resources
Rule-in and rule-out of pre-eclampsia using DELFIA Xpress PlGF 1-2-3 and sFlt-1: PlGF ratio
The objective of this study was to explore and validate thresholds for Placental growth factor (PlGF) and soluble fms-like tyrosine-kinase 1 (s-Flt-1) (as s-Flt-1: PlGF ratio), to rule-in and rule-out disease in women with suspected pre-eclampsia, using DELFIA® Xpress PlGF1-2-3 and sFlt-1 assays. Published in Pregnancy Hypertension, Volume 27, March 2022
Whole Genome Sequencing for Newborn Screening
This article from Medical Technology discusses the ethical and social arguments for whole genome sequencing in newborn screening
First SMA baby identified with our screening solutions in Australia
A newborn baby has been identified as having SMA (spinal muscular atrophy) in Westmead Children’s Hospital in Australia, using a 4-plex SMA, SCID and XLA laboratory developed test
Products may not be licensed in accordance with the laws in all countries, such as the United States, Canada. Please check with your local representative for availability.
Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.
